mhurhangee/ep-ind-claims huggingface dataset:
A transdermal patch having a drug-containing layer comprising oxymorphone or a pharmaceutically acceptable salt thereof, a penetration enhancer, and a pharmaceutically acceptable pressure sensitive adhesive, wherein: - the oxymorphone is present at an amount of 1 - 10% w/w in the drug-containing layer; - the penetration enhancer is present in an amount of 2 - 12 % w/w of the drug-containing layer; - the total amount of adhesive will constitute between 58 and 99% w/w of the drug-containing layer; and - the drug containing layer has a first surface that contacts a backing membrane and a second opposing surface that contacts the skin during use. - the oxymorphone is present at an amount of 1 - 10% w/w in the drug-containing layer; - the penetration enhancer is present in an amount of 2 - 12 % w/w of the drug-containing layer; - the total amount of adhesive will constitute between 58 and 99% w/w of the drug-containing layer; and - the drug containing layer has a first surface that contacts a backing membrane and a second opposing surface that contacts the skin during use.
Underframe for a rail vehicle wagon body, comprising a plurality of longitudinal beams, which are oriented in the longitudinal direction of the underframe, and at least one crossmember which is oriented perpendicularly with respect to the longitudinal beams in the installed position, the longitudinal beams comprising in each case one opening at the mounting position of the crossmember, through which opening the crossmember can be plugged, characterized in that the crossmember can be rotated in the openings about its longitudinal axis, the crossmember being situated in its final mounting position after the termination of the rotational movement, and the longitudinal beams are connected to the crossmember at the intersections to this crossmember by means of a welding method. the crossmember can be rotated in the openings about its longitudinal axis, the crossmember being situated in its final mounting position after the termination of the rotational movement, and the longitudinal beams are connected to the crossmember at the intersections to this crossmember by means of a welding method.
A cross-linkable polymer composition comprising a cross-linkable, non-grafted copolymer containing hydrolysable silane groups, a condensation catalyst, and a cross-linking accelerator, wherein the cross-linkable, non-grafted copolymer containing hydrolysable silane groups is obtained by copolymerizing one or more olefin monomers with an unsaturated silane compound, wherein the condensation catalyst comprises a metal carboxylate, and wherein the cross-linking accelerator is present in an amount of 6 to 75 wt.% based on the total cross-linkable polymer composition. a cross-linkable, non-grafted copolymer containing hydrolysable silane groups, a condensation catalyst, and a cross-linking accelerator, wherein the cross-linkable, non-grafted copolymer containing hydrolysable silane groups is obtained by copolymerizing one or more olefin monomers with an unsaturated silane compound, wherein the condensation catalyst comprises a metal carboxylate, and wherein the cross-linking accelerator is present in an amount of 6 to 75 wt.% based on the total cross-linkable polymer composition. wherein the cross-linkable, non-grafted copolymer containing hydrolysable silane groups is obtained by copolymerizing one or more olefin monomers with an unsaturated silane compound, wherein the condensation catalyst comprises a metal carboxylate, and wherein the cross-linking accelerator is present in an amount of 6 to 75 wt.% based on the total cross-linkable polymer composition.
A compound of the formula I, wherein, R 1 is halogen or haloC 1-6 alkyl; R 2 is hydrogen or halogen; R 3 is hydrogen, halogen, C 1-6 alkyl, haloC 1-6 alkyl, cyano or hydroxy; R 4 is hydrogen; R 5 and R 6 together with nitrogen to which they are attached form pyrrolidinyl, oxopyrrolidinyl, azepanyl, diazepanyl, piperidinyl, hydroxypiperidinyl, carboxypiperidinyl, C 1-6 alkylpiperazinyl, morpholinyl, 2,6-diazaspiro[3.4]octan-6-yl or 2,7-diazaspiro[4.4]nonan-2-yl, wherein pyrrolidinyl is unsubstituted or substituted with one, two or three substituents independently selected from C 1-6 alkyl, C 1-6 alkoxy, hydroxy, carboxy, haloC 1-6 alkyl, carboxyC 1-6 alkyl, hydroxyC 1-6 alky, amino, C 1-6 alkoxycarbonyl, halophenyl, pyridinyl, (diC 1-6 alkylamino)carbonyl and morpholinylcarbonyl; X is-C(=O)-; A 1 is N or CR 7, wherein R 7 is hydrogen, halogen or C 1-6 alkyl; A 2 is N or CH; Y is O; or pharmaceutically acceptable salts, or enantiomers, or diastereomers thereof. R 1 is halogen or haloC 1-6 alkyl; R 2 is hydrogen or halogen; R 3 is hydrogen, halogen, C 1-6 alkyl, haloC 1-6 alkyl, cyano or hydroxy; R 4 is hydrogen; R 5 and R 6 together with nitrogen to which they are attached form pyrrolidinyl, oxopyrrolidinyl, azepanyl, diazepanyl, piperidinyl, hydroxypiperidinyl, carboxypiperidinyl, C 1-6 alkylpiperazinyl, morpholinyl, 2,6-diazaspiro[3.4]octan-6-yl or 2,7-diazaspiro[4.4]nonan-2-yl, wherein pyrrolidinyl is unsubstituted or substituted with one, two or three substituents independently selected from C 1-6 alkyl, C 1-6 alkoxy, hydroxy, carboxy, haloC 1-6 alkyl, carboxyC 1-6 alkyl, hydroxyC 1-6 alky, amino, C 1-6 alkoxycarbonyl, halophenyl, pyridinyl, (diC 1-6 alkylamino)carbonyl and morpholinylcarbonyl; X is-C(=O)-; A 1 is N or CR 7, wherein R 7 is hydrogen, halogen or C 1-6 alkyl; A 2 is N or CH; Y is O;
A kit for identification of an organism comprising: a) a set of primers for amplification of a target nucleic acid sequence that comprises a variable nucleic acid sequence, wherein the variable nucleic acid sequence varies among a group of organisms and is flanked by sequences that are at least relatively conserved between the members of the group of organisms, wherein the primers in the set of primers hybridize to the flanking sequences, and b) multiple detectably distinguishable probe sets, wherein the probes of the probe sets hybridize adjacently to every nucleotide of the variable nucleic acid sequence, and wherein each probe set comprises: (i) a probe labeled with a non-fluorescent quencher, and (ii) a probe labeled with a fluorescent moiety wherein the probe labeled with a fluorescent moiety to the target sequence emits a signal above background if hybridized to the target nucleic acid sequence in the absence of the probe labeled with a non-fluorescent quencher, and wherein if both probes of the probe set are hybridized to the target nucleic acid sequence, the non-fluorescent quencher quenches the signal from the fluorescent moiety. a) a set of primers for amplification of a target nucleic acid sequence that comprises a variable nucleic acid sequence, wherein the variable nucleic acid sequence varies among a group of organisms and is flanked by sequences that are at least relatively conserved between the members of the group of organisms, wherein the primers in the set of primers hybridize to the flanking sequences, and b) multiple detectably distinguishable probe sets, wherein the probes of the probe sets hybridize adjacently to every nucleotide of the variable nucleic acid sequence, and wherein each probe set comprises: (i) a probe labeled with a non-fluorescent quencher, and (ii) a probe labeled with a fluorescent moiety wherein the probe labeled with a fluorescent moiety to the target sequence emits a signal above background if hybridized to the target nucleic acid sequence in the absence of the probe labeled with a non-fluorescent quencher, and wherein if both probes of the probe set are hybridized to the target nucleic acid sequence, the non-fluorescent quencher quenches the signal from the fluorescent moiety. (i) a probe labeled with a non-fluorescent quencher, and (ii) a probe labeled with a fluorescent moiety
A method of operating a display circuit, the display circuit comprising: - a row and column driver driving at least one column line (901, 1000) and at least two row lines (902, 903, 1007, 1008), - a plurality of pixel circuits coupled to the row and column driver, wherein each pixel circuit comprises at least two N-type transistors (904, 905, 1001, 1002) in series connecting the column line to a pixel storage node (909, 1005) of a Liquid Crystal Display, the gates of each one of said two transistors in series being connected to a row line; the method comprising frame write operations wherein the row and column driver writes a new frame onto the LCD and de-stress operations between frame write operations, wherein for a pixel circuit during frame write operations: - a first gate voltage (VGLL) is applied to the gates of the two transistors in series of said pixel circuit, then - a second gate voltage is applied to the gates of the two transistors in series of said pixel circuit to form conduction paths to the pixel storage node of the pixel circuit, and sending charges to the pixel storage node through the conduction paths, characterized in that during de-stress operations between frame write operations, for each pixel circuit: - a third gate voltage and a fourth gate voltage are alternately applied to the gates of each of the two transistors in series of said pixel circuit, wherein the first gate voltage (VGLL) is lower than the fourth gate voltage, which is lower than the third gate voltage, which is lower than the second gate voltage. - a row and column driver driving at least one column line (901, 1000) and at least two row lines (902, 903, 1007, 1008), - a plurality of pixel circuits coupled to the row and column driver, wherein each pixel circuit comprises at least two N-type transistors (904, 905, 1001, 1002) in series connecting the column line to a pixel storage node (909, 1005) of a Liquid Crystal Display, the gates of each one of said two transistors in series being connected to a row line; - a first gate voltage (VGLL) is applied to the gates of the two transistors in series of said pixel circuit, then - a second gate voltage is applied to the gates of the two transistors in series of said pixel circuit to form conduction paths to the pixel storage node of the pixel circuit, and sending charges to the pixel storage node through the conduction paths,
A replication-defective lentiviral packaging vector not encoding a functional HIV-1 Env and lacking a Ψ site and encoding HIV-1 Gag-Pol selected from the group consisting of HIV-1 Gag-Pol of HIV-1 NDK or HIV-1 Gal-Pol of a subtype D HIV-1 characterized in that the Gag-Pol protein comprises a MA protein portion having one or more of the following features: the absence of a glutamic acid at amino acid position 12; the absence of an arginine at amino acid position 15; the absence of a valine at amino acid position 46; and the absence of a leucine at amino acid position 61, wherein amino acid positions are numbered with respect to SEQ ID NO:5. the absence of a glutamic acid at amino acid position 12; the absence of an arginine at amino acid position 15; the absence of a valine at amino acid position 46; and the absence of a leucine at amino acid position 61, wherein amino acid positions are numbered with respect to SEQ ID NO:5.
A separator, comprising: a substrate capable of conducting ions; and at least one dielectric layer capable of conducting ions, wherein: the at least one dielectric layer at least partially covers the substrate, the at least one dielectric layer is a binder-free dielectric layer, and the at least one dielectric layer has a thickness of 1 nanometer to 2;000 nanometers, and the at least one dielectric layer comprises a plurality of dielectric columnar projections. a substrate capable of conducting ions; and at least one dielectric layer capable of conducting ions, wherein: the at least one dielectric layer at least partially covers the substrate, the at least one dielectric layer is a binder-free dielectric layer, and the at least one dielectric layer has a thickness of 1 nanometer to 2;000 nanometers, and the at least one dielectric layer comprises a plurality of dielectric columnar projections. the at least one dielectric layer at least partially covers the substrate, the at least one dielectric layer is a binder-free dielectric layer, and the at least one dielectric layer has a thickness of 1 nanometer to 2;000 nanometers, and the at least one dielectric layer comprises a plurality of dielectric columnar projections.
A system comprising a coupler and a traction beam, wherein the coupler is fixed on the traction beam, and comprises a hook, a mounting seat and a buffering device, wherein, the hook comprises a hook body and a rod body extending from the hook body, the hook body is located outside the traction beam, and the rod body is located inside the traction beam; the mounting seat is provided with a first through hole and a plurality of first mounting holes, and an axial direction of the first through hole is parallel to a longitudinal direction of the traction beam, and an axial direction of the plurality of first mounting holes is parallel to a transverse direction of the traction beam; the mounting seat is located in the traction beam, and is connected to the traction beam by bolts inserted in the first mounting holes; and the buffering device is disposed in the traction beam, and one end of the buffering device passes through the first through hole and connects with the rod body, and the other end of the buffering device abuts against the mounting seat, and wherein the mounting seat is a rectangular block, comprising two end faces and two side faces; the first through hole penetrates through the two end faces, and the plurality of the first mounting holes are located on the two side faces; and the mounting seat is connected to the traction beam by the two side faces. the hook comprises a hook body and a rod body extending from the hook body, the hook body is located outside the traction beam, and the rod body is located inside the traction beam; the mounting seat is provided with a first through hole and a plurality of first mounting holes, and an axial direction of the first through hole is parallel to a longitudinal direction of the traction beam, and an axial direction of the plurality of first mounting holes is parallel to a transverse direction of the traction beam; the mounting seat is located in the traction beam, and is connected to the traction beam by bolts inserted in the first mounting holes; and the buffering device is disposed in the traction beam, and one end of the buffering device passes through the first through hole and connects with the rod body, and the other end of the buffering device abuts against the mounting seat, and wherein the mounting seat is a rectangular block, comprising two end faces and two side faces; the first through hole penetrates through the two end faces, and the plurality of the first mounting holes are located on the two side faces; and the mounting seat is connected to the traction beam by the two side faces.
An anti-VEGF antibody, wherein the antibody comprises a heavy chain variable region, wherein the sequence of the heavy chain variable region of the antibody is set forth in SEQ ID NO: 34.
An electric-field capacitive coupler module, comprising: a first processing unit; a first communication interface coupled to the first processing unit; a second communication interface; and an electric-field capacitive coupler that defines an isolation barrier coupled between the first communication interface and the second communication interface, wherein the second communication interface is coupled to a second processing unit, wherein the second processing unit is operably associated with an electrosurgical generator assembly, wherein: the electric-field capacitive coupler includes two transmit plates and two receive plates, a transmitter for transmitting data across the isolation barrier and coupled to the transmit plates and a receiver for receiving the data and coupled to the receive plates, and the transmit and receive plates are arranged in a stacked configuration. a first processing unit; a first communication interface coupled to the first processing unit; a second communication interface; and an electric-field capacitive coupler that defines an isolation barrier coupled between the first communication interface and the second communication interface, wherein the second communication interface is coupled to a second processing unit, wherein the second processing unit is operably associated with an electrosurgical generator assembly, wherein: the electric-field capacitive coupler includes two transmit plates and two receive plates, a transmitter for transmitting data across the isolation barrier and coupled to the transmit plates and a receiver for receiving the data and coupled to the receive plates, and the transmit and receive plates are arranged in a stacked configuration.
An incubator, comprising: an insulated box including an incubation space surrounded by a plurality of inner faces; a humidifying unit configured to humidify an incubation space; a plurality of heating units (26A-26F) configured to respectively heat the plurality of inner faces, with electric power supplied; and a control unit configured to control the magnitude of electric power supplied to each of the plurality of heating units, wherein: the control unit is configured to, regardless of whether the temperature in a region of the incubator stands at a certain value or not, periodically and repeatedly change the magnitude of electric power supplied to the plurality of heating units (26A-26F), attiming different for each of the plurality of inner faces. an insulated box including an incubation space surrounded by a plurality of inner faces; a humidifying unit configured to humidify an incubation space; a plurality of heating units (26A-26F) configured to respectively heat the plurality of inner faces, with electric power supplied; and a control unit configured to control the magnitude of electric power supplied to each of the plurality of heating units, wherein: the control unit is configured to, regardless of whether the temperature in a region of the incubator stands at a certain value or not, periodically and repeatedly change the magnitude of electric power supplied to the plurality of heating units (26A-26F), attiming different for each of the plurality of inner faces.
A method for real-time determination of an optimal corrected surface of a first bone and/or a second bone forming together an articulation, the first and/or second bones presenting an overgrowth deformation, said corrected surface providing a greater range of motion of the articulation, the method comprising the following steps: i) constructing, from acquired images of the articulation, 3D surface models of the first bone and the second bone and creating 3D voxel models of the first bone and the second bone by filling the inside surface of each 3D surface bone model with a volume of voxel elements; ii) for each of first and second bone voxel models, constructing a coordinate system defined by a center and three axes; iii) applying a motion pattern on the coordinate system of the second bone with respect to the coordinate system of the first bone, a motion pattern being a set of contiguous positions of the first or second bone coordinate systems with respect to the other bone coordinate system, the contiguous positions defining a movement of one bone with respect to the other, wherein said motion pattern is initially loaded from a data base of predefined motion patterns; iv) determining a resection volume from said motion pattern as being the union of interpenetration volumes of the first or second bone voxel model with the other bone voxel model for each position of the motion pattern, v) determining the optimal corrected surface by virtually removing said resection volume from the first and/or the second bone voxel model. i) constructing, from acquired images of the articulation, 3D surface models of the first bone and the second bone and creating 3D voxel models of the first bone and the second bone by filling the inside surface of each 3D surface bone model with a volume of voxel elements; ii) for each of first and second bone voxel models, constructing a coordinate system defined by a center and three axes; iii) applying a motion pattern on the coordinate system of the second bone with respect to the coordinate system of the first bone, a motion pattern being a set of contiguous positions of the first or second bone coordinate systems with respect to the other bone coordinate system, the contiguous positions defining a movement of one bone with respect to the other, wherein said motion pattern is initially loaded from a data base of predefined motion patterns; iv) determining a resection volume from said motion pattern as being the union of interpenetration volumes of the first or second bone voxel model with the other bone voxel model for each position of the motion pattern, v) determining the optimal corrected surface by virtually removing said resection volume from the first and/or the second bone voxel model.
Yarn guide unit for a textile machine comprising: - a yarn guide to guide a yarn; and - a belt drive with a drive belt on which the yarn guide is affixed, with a first and with a second pulley (18, 20) around which the drive belt is guided, and with a controllable and/or adjustable drive motor to drive one of the two pulleys (18, 20), characterised in that the two pulleys (18, 20) are each provided with one flange disc only to guide the drive belt laterally and wherein the two pulleys (18, 20) are arranged with their axes of rotation (18a, 20a) tilted in opposite directions relative to a line perpendicular to a belt plane along which the drive belt lies in such a way that the drive belt is guided with its side edge against the flange discs of the two pulleys (18, 20) while the yarn guide unit is running. - a yarn guide to guide a yarn; and - a belt drive with a drive belt on which the yarn guide is affixed, with a first and with a second pulley (18, 20) around which the drive belt is guided, and with a controllable and/or adjustable drive motor to drive one of the two pulleys (18, 20),
An in vitro method for prediction of clinical outcome in a subject, the method comprising: (a) receiving a plurality of blood or serum samples collected from a subject having, or suspected of having or developing, a hepatic disorder, following oral administration of an isotopically labeled cholic acid selected from 24- 13 C cholic acid and 2,2,4,4- 2 H cholic acid to the subject, wherein no cholic acid compound is intravenously co-administered, and wherein the samples have been collected from the subject over intervals for a period of 90 minutes or less after administration; and (b) measuring the clearance of the orally administered isotopically labeled cholic acid as an indicator of hepatic function for prediction of clinical outcome in the subject, wherein the measuring step comprises quantifying the isotopically labeled cholic acid in the samples by HPLC-MS. (a) receiving a plurality of blood or serum samples collected from a subject having, or suspected of having or developing, a hepatic disorder, following oral administration of an isotopically labeled cholic acid selected from 24- 13 C cholic acid and 2,2,4,4- 2 H cholic acid to the subject, wherein no cholic acid compound is intravenously co-administered, and wherein the samples have been collected from the subject over intervals for a period of 90 minutes or less after administration; and (b) measuring the clearance of the orally administered isotopically labeled cholic acid as an indicator of hepatic function for prediction of clinical outcome in the subject, wherein the measuring step comprises quantifying the isotopically labeled cholic acid in the samples by HPLC-MS.